Therapeutic Evaluation Etanercept, a Tumor Necrosis Factor Antagonist, in Experimental Heatstroke

Project: A - Government Institutionb - Ministry of Science and Technology

Description

In terms of clinical burden on the society and number of deaths occurring due to heat illness, hyperthermic brain injury is the third largest killer in the world after the cardiovascular and traumatic insults to the central nervous system. In spite of the seriousness of this problem, studies regarding effects of heat on the CNS are largely ignored. Etanercept is a tumor necrosis factor antagonist with antiinflammatory effects. Etanercept has demonstrated beneficial activity in many inflammatory diseases. In our first year study, we attempt to investigate the role of tumor necrosis factor-αin the pathogenesis of heatstroke and evaluate the therapeutic effects of Etanercept in a heatstroke model of anesthetized rats. In anesthetized rats models, although the survival time (interval between the start of heat exposure and animal death) values during heatstroke were significantly prolonged by various agents or methods, but all the animals died. The death for the death of these anesthetized animals may be related to anesthesia state. To ascertain whether there was durable improvement in survival, unanesthetized and unrestrained animals with or without Etanercept treatment should be conduced in our second year study. Recently, it has been shown that hyperbaric oxygen therapy (100% O2 at 250 kpa) may resuscitate rats that had a heatstroke by decreasing multiple organ dysfunction. In our third year study, we attempt to ascertain whether combined Etanercept and hyperbaric oxygen therapy would be able to provide additional protection in the anesthetized rats with heatstroke.
StatusFinished
Effective start/end date6/2/117/31/11

Keywords

  • heatstroke
  • Etanercept
  • tumor necrosis factor
  • inflammation
  • apoptosis
  • oxidative stress